China’s vaccine scandal highlights Hong Kong’s special status

By Frank Ching

Aug 14, 2018 12:26 am

FRANK CHING

IN mid-July, China’s state drug administration ordered Changsheng Bio-technology, a company headquartered in Changchun, in northeastern China, to stop production of rabies vaccines after it uncovered evidence of forged data. At about the same time, the company was fined 3.4 million yuan ($502,000) for the production of inferior DPT vaccines last year.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.